Natural antimicrobials and their role in vaginal health: A short review
2008 (English)In: International Journal of Probiotics and Prebiotics, Vol. 3, no 4, 219-230 p.Article in journal (Refereed) Published
Lactobacillus species maintain the vaginal ecosystem in a healthy condition by production of antimicrobial substances. Depletion of lactobacilli in the vagina results in bacterial vaginosis (BV), where the normal flora is replaced by several bacterial pathogens, usually Gardnerella vaginalis and obligate anaerobes. BV may cause complications such as premature labor, low birth weight and increased risk of HIV acquisition. The currently recommended antibiotic treatments for BV are not always effective and often lead to reoccurrence of the infection. In many cases, this is due to the antibiotic-resistant forms of the pathogens. Therefore, there is an interest in the development of treatments using antimicrobials derived primarily from Lactobacillus spp., such as ribosomally produced antimicrobial peptides (bacteriocins) and lactic acid. These substances effectively inhibit pathogenic bacteria, are safe and do not pose any threat to healthy vaginal Lactobacillus spp. It may be possible to find an effective treatment against BV while reducing the infection's reoccurrence and the treatment-related complications through hurdle technology. This would be achieved by combining antimicrobials produced by Lactobacillus spp. with different natural antimicrobials obtained from plants or other non-pathogenic organisms. Copyright
Place, publisher, year, edition, pages
2008. Vol. 3, no 4, 219-230 p.
Bacterial vaginosis, Bacteriocins, Lactic acid, Lactobacilli, Natural antimicrobials, acidform, aluminum derivative, amphora, bacteriocin, bacteriocin hv219, clindamycin, edetic acid, ellen, hydrogen peroxide, lactacyd vaginal gel, lactal, lactate sodium, lactocin 160, metronidazole, myconip, nisin, pentocin tv35b, placebo, polycarbophil, polylysine, polypeptide antibiotic agent, probiotic agent, saponin derivative, unclassified drug, unindexed drug, usnic acid, vagiforte, VSL3, zinc derivative, zinc sulfate, absence of side effects, anaerobic bacterium, antibacterial activity, antibiotic resistance, bacterial flora, clinical trial, drug potentiation, drug safety, Gardnerella vaginalis, gas embolism, human, Human immunodeficiency virus infection, infection risk, Lactobacillus, low birth weight, nonhuman, premature labor, recurrent disease, review, risk reduction, subcutaneous emphysema, vaginitis
IdentifiersURN: urn:nbn:se:kth:diva-154190ScopusID: 2-s2.0-60749120939OAI: oai:DiVA.org:kth-154190DiVA: diva2:755426
QC 201411142014-10-142014-10-142014-10-14Bibliographically approved